Replies to post #112313 on Biotech Values

[DewDiligence]

…if you are correct about PPHM management intentions...then I guess we can expect really shabby results from their phase II HCV trial?

It’s even worse than that—the phase-2 HCV trial PPHM says it intends to run is patently unethical, IMO. Insofar as there are no hard data showing that Bavituximab has efficacy against HCV, the trial arm where patients receive Bavituximab + ribavirin is tantamount to ribavirin monotherapy, which could have adverse consequences for patients who seek follow-up therapy with a regimen including ribavirin.

Moreover, Telaprevir and/or Boceprevir will likely be on the US market in about four months, which is sooner than PPHM’s trial will be able to recruit and dose all patients.

In short, any HCV clinician who recommends that a patient enroll in PPHM’s trial ought to have a good malpractice policy with a paid-up premium.